GlobeImmune drug has positive trial
LOUISVILLE – GlobeImmune Inc. drug GI-5005 showed positive results in a phase 2 clinical trial, the company recently announced.
The drug was coupled with pegylated interferon and ribavirin, which is considered standard of care, and compared to standard of care alone. The trial included 140 patients with chronic genotype 1 hepatitis C.
Patients who received Louisville-based GlobeImmune’s drug experienced a 94 percent early virologic response rate.
SPONSORED CONTENT
“We believe that this increase in EVR over standard of care alone may indicate that the GI-5005 mechanism of action is complementary to the current standard care,” Eric Lawitz, the study’s lead author, said in a statement.
The study also showed a decrease in the number of patients with worsening serum fibrosis scores after 24 weeks for those that received GI-5005 as well as improved serum Actitest scores and an improvement in normalization of alanine transaminase. Serum fibrosis, serum Actitest and alanine transaminase all help determine the stage of liver damage.
LOUISVILLE – GlobeImmune Inc. drug GI-5005 showed positive results in a phase 2 clinical trial, the company recently announced.
The drug was coupled with pegylated interferon and ribavirin, which is considered standard of care, and compared to standard of care alone. The trial included 140 patients with chronic genotype 1 hepatitis C.
Patients who received Louisville-based GlobeImmune’s drug experienced a 94 percent early virologic response rate.
“We believe that this increase in EVR over standard of care alone may indicate that the GI-5005 mechanism of action is complementary to the current standard care,” Eric Lawitz, the study’s lead author, said in a statement.
The…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
